Back to discover
§ The cross-read
ABT vs SYK
ABT has a published report; SYK is awaiting first coverage, so the editorial contrast below leans on the live data row alone.
Fair-value ladder
Fair-value ladder unavailable — one or both tickers have no published mid fair value.
Aligned scorecards
Aligned scorecards unavailable — at least one ticker has no published 9-category scorecard yet.
| ABTAbbott Laboratories | SYKStryker Corporation | |
|---|---|---|
| Trend | - | - |
| Price | - | - |
| Fair value | - | - |
| FV range | - | - |
| Upside | - | - |
| Rating | احتفاظ | احتفاظ |
| Confidence | - | - |
| Moat | - | - |
| Archetype | - | - |
| Sector | Health Care | Health Care |
| Analyzed | - | - |
9-category scorecards
ABT
Abbott Laboratories
Valuation
1.5/10
0.11x
Management
6.4/10
0.11x
Balance Sheet
6.0/10
0.11x
Profitability
5.5/10
0.11x
Revenue Growth
6.0/10
0.11x
Risk Assessment
7.5/10
0.11x
Competitive Moat
9.0/10
0.11x
Earnings Quality
3.5/10
0.11x
Capital Efficiency
5.0/10
0.11x
Weighted Overall
5.6/10
SYK
No published scorecard yet.